Navigation Links
Dendreon Announces Plans to Seek Marketing Authorization for PROVENGE in Europe
Date:1/7/2011

d for transmissible infectious diseases.

The safety evaluation of PROVENGE was based on 601 prostate cancer patients in four randomized clinical trials who underwent at least one leukapheresis procedure. The most common adverse events (incidence greater than or equal to 15%) reported in patients in the PROVENGE group are chills, fatigue, fever, back pain, nausea, joint ache, and headache. Serious adverse events reported in patients in the PROVENGE group include acute infusion reactions (occurring within 1 day of infusion) and cerebrovascular events. In controlled clinical trials, severe (Grade 3) acute infusion reactions were reported in 3.5% of patients in the PROVENGE group. Reactions included chills, fever, fatigue, asthenia, dyspnea, hypoxia, bronchospasm, dizziness, headache, hypertension, muscle ache, nausea, and vomiting. No Grade 4 or 5 acute infusion reactions were reported in patients in the PROVENGE group.

To fulfill a post marketing requirement and as a part of the company's ongoing commitment to patients, Dendreon will conduct a registry of approximately 1,500 patients to further evaluate a small potential safety signal of cerebrovascular events. In four randomized clinical trials of PROVENGE in prostate cancer patients, cerebrovascular events were observed in 3.5% of patients in the PROVENGE group compared with 2.6% of patients in the control group.

For more information on PROVENGE, please see the full Prescribing Information at www.provenge.com or call Dendreon ON Call at 1-877-336-3736

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
2. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
3. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
4. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
5. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
6. Dendreon Reports Third Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
8. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
9. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
10. Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
11. Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Professor of Engineering at the University of Delaware, ... problems in energy engineering, environmental sustainability and electronics. ... porous rock with a well-defined, crystalline structure. At ... precisely decided that zeolites can separate molecules with ... angstrom (one-tenth of a nanometer), making them useful ...
(Date:7/24/2014)... 24, 2014 Your cell phone ... modeling lithium-ion battery storage capacity. , New research ... theoretical model created at Lawrence Livermore National ... predicts how carbon components will perform as electrodes. ... the urgent need for higher-performance batteries. Several key ...
(Date:7/24/2014)... 2014 2014 Deep Research Report ... a professional and in-depth research report on Potassium ... basic information, including its definition, classification, application, ... research covers the international market analysis, including China’s ... covering macroeconomic environment & economic situation analysis, the ...
(Date:7/24/2014)... The first part of the session on “Best ... Studies” will cover comprehensive clinical support in early phase ... R&D costs and declining industry success in getting products ... collected in early Phase I/IIa study data to make ... development. , Next, the presenters will examine steps to ...
Breaking Biology Technology:University of Delaware researcher describes new approach for creating organic zeolites 2Getting More Life out of Lithium-ion Batteries 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2
... Jerusalem, July 21, 2010 -- Scientists from the Hebrew ... is possible to greatly expand the memory capacity of ... on silica nanoparticles combined with protein molecules obtained from ... say, they have developed an alternative avenue to miniaturize ...
... 21 The Lucian Leape Institute at the National ... special evening program at its Third Annual Forum & ... Blumenthal, M.D., M.P.P., will deliver a keynote address at the ... patient safety lever and the focus placed on its development ...
... DALLAS , July ... report "Bioinformatics Market - Advanced Technologies, Global,Forecast and Winning ... bioinformatics market is,expected to reach a $8.3 billion ... from,2009-2014. While knowledge management formed the largest submarket is ...
Cached Biology Technology:Protein from poplar trees can be used to greatly increase computer capacity 2David Blumenthal, HHS National Coordinator for Health Information Technology, to Speak at Lucian Leape Institute Third Annual Forum & Gala on Sept. 16 2David Blumenthal, HHS National Coordinator for Health Information Technology, to Speak at Lucian Leape Institute Third Annual Forum & Gala on Sept. 16 3David Blumenthal, HHS National Coordinator for Health Information Technology, to Speak at Lucian Leape Institute Third Annual Forum & Gala on Sept. 16 4MarketsandMarkets: Global Bioinformatics Market Worth $8.3 billion by 2014 2MarketsandMarkets: Global Bioinformatics Market Worth $8.3 billion by 2014 3MarketsandMarkets: Global Bioinformatics Market Worth $8.3 billion by 2014 4
(Date:7/24/2014)... that successfully treated lupus in mice, a biomedical engineer at ... expand his research to a new version of the drug ... diseases., Chandra Mohan, Hugh Roy and Lillie Cranz Cullen Endowed ... in Arthritis Research & Therapy outlining the use of a ... the number of cases of lupus-related kidney disease., He now ...
(Date:7/24/2014)... , July 24, 2014 NXT-ID, Inc., (NXTD: OTCQB) a ... announces its next generation smart wallet, Wocket™, was recently the topic ... Finley interviewed Gino Pereira , CEO of ... minutes. Mr. Gino Pereira ... full of credit cards and walks host Anita ...
(Date:7/23/2014)... been abused or neglected early in life are ... health problems. In a new study, scientists have ... activated, which has implications for children,s long-term development. ... individual characteristics and genetics interacted with that child,s ... problems emerge. In the new study, researchers were ...
Breaking Biology News(10 mins):Biomedical engineer looks at new applications for novel lupus drug 2Biomedical engineer looks at new applications for novel lupus drug 3Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 2Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 3Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 4Stress tied to change in children's gene expression related to emotion regulation, physical health 2Stress tied to change in children's gene expression related to emotion regulation, physical health 3
... reason for the weight-conscious to drink fat free milk,at breakfast ... of,the American Journal of Clinical Nutrition . Researchers in ... increase,satiety, or a feeling of fullness, and led to decreased ... drink. The milk drinkers ate,about 50 fewer calories (or nearly ...
... Notch signaling helps determine the fate of a number ... humans. In an article that appears in the current issue ... of Medicine report that a new finding about the Notch ... fly could explain the mystery behind an immunological disorder called ...
... Dissolved organic carbon (DOC) losses from tile drains ... This is particularly important in the eastern corn belt ... management practices, such as manure application, can play a ... organic carbon is applied to or injected into the ...
Cached Biology News:Drinking milk in the morning may help stave off lunchtime hunger 2Fate in fly sensory organ precursor cells could explain human immune disorder 2Fate in fly sensory organ precursor cells could explain human immune disorder 3Study of agricultural watersheds and carbon losses 2
... Anti-Natural Killer Cell Receptor-P1, clone ... Hybridoma produced by ... BALB/c mice immunized (BALB/c X ... cells and mouse myeloma cellline. ...
... monoclonal [YPF19] to Yersinia pestis ... Yersinia pestis . Immunogen: ... Yersinia pestis vaccine strain EV76. ... recognises Y.pestis F1 capsular antigen. There ...
Rabbit polyclonal to ZFP200 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGKSFNHKTNLNKHER (Human) Entrez Gene ID: 7752 Swiss Protein ID: P98182...
Anti-human C3a/C3a des-Arg (neo-epitope), Clone 2991, Monoclonal Antibody...
Biology Products: